Characterization the prognosis role and effects of snoRNAs in melanoma patients

• Published in: Experimental dermatology Vol. 33; no. 1; pp. e14944 - n/a
• Main Authors: Wang, Lei‐Yun, Song, Jia‐Nan, Chen, Yi‐Xuan, Zhu, Ying, Ren, Hui‐Li, Li, Qiu‐Qi, Zhang, Shao‐Hui
• Format: Journal Article
• Language: English
• Published: Denmark Wiley Subscription Services, Inc 01-01-2024
• Subjects: Biomarkers; Immune checkpoint inhibitors; immune microenvironment; Immunotherapy; Melanoma; Metastases; Nucleoli; Patients; prognostic model; SnoRNA; Tumor microenvironment; Tumors; melanoma; immune microenvironment; immune checkpoint inhibitors; SnoRNA; prognostic model
• ISSN: 0906-6705; 1600-0625
• DOI: 10.1111/exd.14944

Melanoma is a melanocyte‐derived malignant cancer and is known for its early metastasis and high mortality rates. It is a highly cutaneous tumour disease that could be related to the abnormal immune microenvironment, and the identification of reliable diagnostic and prognostic markers is crucial for improving patient outcomes. In the search for biomarkers, various types of RNAs have been discovered and recognized as reliable prognostic markers. Among these, small nucleolar RNAs (snoRNAs) have emerged as a promising avenue for studying early diagnosis and prognostic markers in tumours due to their widespread presence in tissues, tumour specificity and stability. In our study, we analysed snoRNAs data from melanoma samples in the TCGA‐SKCM cohort and developed a prognostic model comprising 12 snoRNAs (SNORD9, SNORA31, SNORD14E, SNORA14A, SNORA5A, SNORD83A, SNORA75, AL096855, AC007684, SNORD14A, SNORA65 and AC004839). This model exhibited unique prognostic accuracy and demonstrated a significant correlation with the immune infiltration tumour microenvironment. Additionally, analysis of the GSE213145 dataset, which explored the sensitivity and resistance of immune checkpoint inhibitors, further supported the potential of snoRNAs as prognostic markers for immunotherapy. Overall, our study contributes reliable prognostic and immune‐related biomarkers for melanoma patients. These findings can offer valuable insights for the future discovery of novel melanoma treatment strategies and hold promise for improving clinical outcomes in melanoma patients.